Cover Image
Market Research Report

Thromboembolism - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 200494
Published Content info 111 Pages
Delivery time: 1-2 business days
Price
Back to Top
Thromboembolism - Pipeline Review, H2 2019
Published: August 30, 2019 Content info: 111 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 8, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11357IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thromboembolism - Overview
  • Thromboembolism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Thromboembolism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Thromboembolism - Companies Involved in Therapeutics Development
    • Accu-Break Pharmaceuticals Inc
    • Bayer AG
    • Bristol-Myers Squibb Co
    • China Biologic Products Holdings Inc
    • CSPC Pharmaceutical Group Ltd
    • Daiichi Sankyo Co Ltd
    • F. Hoffmann-La Roche Ltd
    • GC Pharma
    • Ionis Pharmaceuticals Inc
    • Laboratorios Farmaceuticos Rovi SA
    • Ono Pharmaceutical Co Ltd
    • Portola Pharmaceuticals Inc
    • Tasly Pharmaceutical Group Co Ltd
    • Tetherex Pharmaceuticals Corp
    • Verseon Corp
  • Thromboembolism - Drug Profiles
    • antithrombin III (human) - Drug Profile
    • betrixaban - Drug Profile
    • BMS-986177 - Drug Profile
    • Drugs for Pulmonary Embolism - Drug Profile
    • DS-1040 - Drug Profile
    • edoxaban tosylate - Drug Profile
    • enoxaparin sodium - Drug Profile
    • GC-2107 - Drug Profile
    • IONIS-FXIRx - Drug Profile
    • Lysimab - Drug Profile
    • ONO-7684 - Drug Profile
    • osocimab - Drug Profile
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
    • Recombinant Protein for Thromboembolism - Drug Profile
    • rivaroxaban - Drug Profile
    • SelK-2 - Drug Profile
    • SYHA-136 - Drug Profile
    • TAP-ANV - Drug Profile
    • tecarfarin sodium - Drug Profile
    • TRX-1 - Drug Profile
    • urokinase - Drug Profile
    • VE-1902 - Drug Profile
    • VE-2851 - Drug Profile
    • warfarin potassium - Drug Profile
    • YG-001 - Drug Profile
    • Zifa-01 - Drug Profile
  • Thromboembolism - Dormant Projects
  • Thromboembolism - Discontinued Products
  • Thromboembolism - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Thromboembolism, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Thromboembolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2019
  • Thromboembolism - Pipeline by Bayer AG, H2 2019
  • Thromboembolism - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Thromboembolism - Pipeline by China Biologic Products Holdings Inc, H2 2019
  • Thromboembolism - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019
  • Thromboembolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Thromboembolism - Pipeline by GC Pharma, H2 2019
  • Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
  • Thromboembolism - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2019
  • Thromboembolism - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2019
  • Thromboembolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019
  • Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, H2 2019
  • Thromboembolism - Pipeline by Verseon Corp, H2 2019
  • Thromboembolism - Dormant Projects, H2 2019
  • Thromboembolism - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Thromboembolism - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Thromboembolism, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top